New Jersey: Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics on Friday announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. more